Thymosin Alpha-1

evidence score
peptide
Prescription Only
Tα1TA-1Zadaxin+2 more

Thymosin Alpha-1 (Tα1) is a naturally occurring 28-amino acid peptide derived from thymosin fraction 5 of the thymus gland. It is FDA-approved in the US as an orphan drug and approved in 35+ countries (as Zadaxin) for chronic hepatitis B and C, cancer immunotherapy adjunct, DiGeorge syndrome, and severe sepsis. It is a potent thymic hormone that matures naive T-cells, enhances NK cell activity, and restores immune competence in immunocompromised states. Growing use in biohacking/longevity communities for immune optimization, chronic infections, and post-viral syndromes (Long COVID). Extraordinarily safe profile across decades of clinical use.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical
1.6 mg
0.8 mgRange3.2 mg
Frequency2x/week to daily depending on indication

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~2 hours
OnsetImmunological effects within days to weeks; clinical outcomes 4-12 weeks
DurationOngoing with continued dosing; effects sustained during treatment
Routes
subcutaneous_injection

Evidence Score

0 studies indexed
Scoring Factors
Volume(40%)
Quality(30%)
Sample Size(10%)
Consistency(10%)
Replication(5%)
Recency(5%)
Evidence Levels
AScore ≥75 with at least 1 meta-analysis and 3+ RCTs
BScore ≥50 with at least 1 RCT or meta-analysis
CScore ≥25 — observational or animal evidence only
DScore <25 — very limited or preclinical data

Plain-English Snapshot

Thymosin Alpha-1 is currently categorized as a peptide compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

TLR2/9 agonism activates dendritic cells; T-cell differentiation (Th1 skew) via IL-12/IFN-γ; NK cell maturation; upregulates MHC class I expression on tumor cells

Practical Context

Strongest current signals

No indexed study summaries yet.

Compound Profile